151 related articles for article (PubMed ID: 29089644)
1. Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis.
Tefferi A; Lasho TL; Finke C; Gangat N; Hanson CA; Ketterling RP; Pardanani A
Leukemia; 2018 Mar; 32(3):837-839. PubMed ID: 29089644
[No Abstract] [Full Text] [Related]
2. ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden.
Wang YH; Lin CC; Lee SH; Tsai CH; Wu SJ; Hou HA; Huang TC; Kuo YY; Yao M; Chang K; Lin CW; Lin YC; Tien FM; Chou WC; Tang JL; Tien HF
Blood Cancer J; 2020 Oct; 10(10):99. PubMed ID: 33046688
[No Abstract] [Full Text] [Related]
3. Spectrum of
Rotunno G; Mannarelli C; Brogi G; Pacilli A; Gesullo F; Mannelli F; Fiaccabrino S; Sordi B; Paoli C; Marone I; Rumi E; Manfredini R; Barosi G; Cazzola M; Vannucchi AM; Guglielmelli P
Blood; 2019 Jun; 133(26):2802-2808. PubMed ID: 31076447
[No Abstract] [Full Text] [Related]
4. Highly variable mutational profile of ASXL1 in myelofibrosis.
Sorigué M; Ribera JM; García O; Cabezón M; Vélez P; Marcé S; Xicoy B; Fernández C; Buch J; Cortes M; Plensa E; Gallardo D; Boqué C; Feliu E; Zamora L
Eur J Haematol; 2016 Oct; 97(4):331-5. PubMed ID: 26714837
[TBL] [Abstract][Full Text] [Related]
5. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
6. ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis.
Guo Y; Zhou Y; Yamatomo S; Yang H; Zhang P; Chen S; Nimer SD; Zhao ZJ; Xu M; Bai J; Yang FC
Leukemia; 2019 May; 33(5):1287-1291. PubMed ID: 30651633
[No Abstract] [Full Text] [Related]
7. Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis.
Tefferi A; Lasho TL; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Br J Haematol; 2018 Nov; 183(4):678-681. PubMed ID: 29171022
[No Abstract] [Full Text] [Related]
8. Identification of driver and subclonal mutations in ASXL1 and IDH1/IDH2 genes in an Argentine series of patients with myelofibrosis.
Scheps K; Meyer C; Bestach Y; Enrico A; Bengió R; Rodríguez-Zubieta M; Rivas M; De Brasi C; Larripa I
Int J Lab Hematol; 2018 Aug; 40(4):e82-e86. PubMed ID: 29761621
[No Abstract] [Full Text] [Related]
9. ASXL1 mutations in primary and secondary myelofibrosis.
Ricci C; Spinelli O; Salmoiraghi S; Finazzi G; Carobbio A; Rambaldi A
Br J Haematol; 2012 Feb; 156(3):404-7. PubMed ID: 21923651
[No Abstract] [Full Text] [Related]
10. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
11. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
Luque Paz D; Riou J; Verger E; Cassinat B; Chauveau A; Ianotto JC; Dupriez B; Boyer F; Renard M; Mansier O; Murati A; Rey J; Etienne G; Mansat-De Mas V; Tavitian S; Nibourel O; Girault S; Le Bris Y; Girodon F; Ranta D; Chomel JC; Cony-Makhoul P; Sujobert P; Robles M; Ben Abdelali R; Kosmider O; Cottin L; Roy L; Sloma I; Vacheret F; Wemeau M; Mossuz P; Slama B; Cussac V; Denis G; Walter-Petrich A; Burroni B; Jézéquel N; Giraudier S; Lippert E; Socié G; Kiladjian JJ; Ugo V
Blood Adv; 2021 Mar; 5(5):1442-1451. PubMed ID: 33666653
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
Wang Z; Liu W; Wang M; Li Y; Wang X; Yang E; Ming J; Quan R; Hu X
Ann Hematol; 2021 Feb; 100(2):465-479. PubMed ID: 33386934
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular genetic characterization of myelofibrosis.
Hobbs GS; Rampal RK
Curr Opin Hematol; 2015 Mar; 22(2):177-83. PubMed ID: 25635755
[TBL] [Abstract][Full Text] [Related]
14. The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis.
Li B; Xu Z; Li Y; Peter Gale R; Song Z; Ai X; Qin T; Zhang Y; Zhang P; Huang G; Xiao Z
Am J Hematol; 2016 Jul; 91(7):E320-1. PubMed ID: 27059877
[No Abstract] [Full Text] [Related]
15. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutations and polymorphisms in primary myelofibrosis.
Raza S; Viswanatha D; Frederick L; Lasho T; Finke C; Knudson R; Ketterling R; Pardanani A; Tefferi A
Am J Hematol; 2012 Feb; 87(2):204-6. PubMed ID: 22052707
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
Alshemmari SH; Rajan R; Emadi A
Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
[TBL] [Abstract][Full Text] [Related]
18. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.
Barraco D; Elala YC; Lasho TL; Begna KH; Gangat N; Finke C; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
Blood Cancer J; 2016 Apr; 6(4):e415. PubMed ID: 27058230
[No Abstract] [Full Text] [Related]
19. Prognosis of Primary Myelofibrosis in the Genomic Era.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
[TBL] [Abstract][Full Text] [Related]
20. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
